Clinical trials: Depressive Disorder NOS
Depression
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches.
- Trial name
- EMBARC (NCT01407094)
- Testing
- Sertraline, BupropionXL
- Where
- 4 sites in United States
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Major Depression in Remission
Feasibility of Adherence to Light Therapy
In this feasibility study, we propose an important question: What factors will affect participant adherence to the daily use of light therapy for maintenance treatment of depression? To answer this question, we will conduct a…
- Trial name
- NCT04944758
- Testing
- Light therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of British Columbia
Bipolar Disorder, Depression
Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
This study will develop strategies for early detection and prevention of mood disorders and associated impairment in adolescent children of parents with bipolar disorder.
- Trial name
- NCT00338806
- Testing
- Interpersonal psychotherapy for prevention with adolescents, Educational clinical monitoring
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA)
An Investigation of Early Life Stress and Depression
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).
- Trial name
- NCT01701258
- Testing
- Amisulpride
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Depression, Opioid-use Disorder
Ketamine for the Treatment of Opioid Use Disorder and Depression
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine…
- Conditions
- Depression, Opioid-use Disorder, Opioid Abuse
- Trial name
- NCT04177706
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
TBI, Major Depression
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
This research is being done to see if a drug called escitalopram (Lexapro) is helpful to people who are suffering from depression after traumatic brain injury (TBI).
- Conditions
- TBI, Major Depression, Other Psychiatric Disorders
- Trial name
- NCT01368432
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Depression
Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression
This study will compare the effectiveness of telephone versus face-to-face administration of cognitive behavioral therapy in treating people with depression.
- Trial name
- NCT00498706
- Testing
- Telephone-administered cognitive behavioral therapy (T-CBT), Face-to-face administered CBT (FtF-CBT)
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Connectivity Affecting the Antidepressant REsponse Study
It can be difficult to achieve remission in individuals with late-life depression (LLD) and they often require aggressive treatment. This challenge is in part due to age-related vascular changes that are common in LLD.
- Trial name
- CAARE (NCT02332291)
- Testing
- Escitalopram, Bupropion XL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt University Medical Center
Major Depressive Disorder, Healthy Controls
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs.
- Trial name
- UNIKET (NCT05046184)
- Testing
- Ketamine Hydrochloride, Midazolam injection
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal…
- Trial name
- NCT03434041
- Testing
- Esketamine 56 mg, Esketamine 84 mg, Duloxetine (Oral Antidepressant)
- Where
- 30 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Dysthymia Disorder
Oxytocin Add-on for Stable Depressed Patients
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve depression symptoms in patients with Major Depressive Disorder (MDD) or Dysthymia Disorder.
- Trial name
- NCT01211756
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- David Feifel
Study Adherence, Depressive Disorder
Message-Based Psychotherapy and Digital Treatment Sequences for Depression
This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy.
- Trial name
- NCT04513080
- Testing
- Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
- Where
- United States
- Volunteers
- 1,184 people
- Sponsor
- Talkspace
Major Depressive Disorder
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT04985942
- Testing
- Lumateperone
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 485 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Safety Study in Participants With Major Depressive Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to…
- Trial name
- NCT01155661
- Testing
- LY2216684 (edivoxetine), SSRI
- Where
- 48 sites in United States, Brazil and 5 more
- Volunteers
- 608 people
- Sponsor
- Eli Lilly and Company